Gargoloff P, García-Bonetto G, Galeno R, Ortíz E, Godino A, Gris E, Adrianzén C

Language: Spanish
References: 29
Page: 167-175
PDF size: 568.82 Kb.

ABSTRACT

Objective: to describe the clinical outcomes of the Schizophrenia Outpatients Health Outcomes (SOHO) study in Argentina. Methods: naturalistic, observational, prospective and 3-year study that compared outpatients who started or changed to oral olanzapine or to any other antipsychotic (other AP). The effectiveness was measured using the Global Clinical Impression Schizophrenia Scale. Other effectiveness measures and emergent adverse events were recorded. Results: Argentina enrolled 186 patients on Olanzapine and 175 on other APs. Patients on olanzapine improved more and faster than patients in Other AP group with a statistical difference at the first and second year. Rates of clinical response were statistically greater on olanzapine vs other AP (92.4, 75.4%, respectively, p = 0.0001) and rates of relapse were similar between groups (25.9, 28%, respectively, p = 0.7436). Rates of extrapyramidal symptoms and tardive dyskinesia were statistically lower in the olanzapine group and weight gain was statistically greater during the first but not at the third year. More patients discontinued their prescribed antipsychotic due to lack of or incomplete response than due to intolerability. Conclusions: these results support the observations of faster and greater clinical improvement with olanzapine than other AP in real-world settings. A greater proportion of patients in the olanzapine group gained weight ≥ 7% from baseline to the first year and second years without statistical difference. At the third year a greater proportion of patients in other AP group gained weight ≥ 7% from baseline without statistical difference vs olanzapine. Some limitations in the design and heterogeneity of the other AP group and the nature of observational studies must be taken in account to interpret these results.

REFERENCES

1. Kane JM, Schizophrenia. N Engl J Med 1996;334:34-41.

2. Fleischhacker W, Hummer M. Drug treatment of schizophrenia in the 1990s: achievements and future possibilities in optimising outcomes. Drugs 1997;53:915-29.

3. Marder SR. Antipsychotic drugs and relapse prevention. Schizophr Res 1999;35:87-92.

4. Arana GW. An overview of side effects caused by typical antipsychotic. J Clin Psychiatry 2000;61Suppl 8:5-11.

5. Weiden PJ, Shaw E, Man JJ. Causes of neuroleptic noncompliance. Psychiatr Ann 1986;16:571-5.

6. American Psychiatric Association. Practice guidelines for the treatment of psychiatric disorders. Compendium 2002. APA, Washington DC, 2002.

7. National Collaborating Centre for Mental Health. Schizophrenia: Full national clinical guideline on core interventions in primary and secondary care. The Royal College of Psychiatrists. TheBritish Psychological Society, 2003; London, 2003.

8. Miller AL, Hall CS, Buchanan RW, Bucley PF, Chiles JA, ComleyRR, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65:500-8.

9. Canadian Psychiatric Association. Clinical Practice Guidelines: Treatment of schizophrenia. The Canadian Journal of Psychiatry 2005; 50 (Suppl 1): 1S-56S

10. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.

11. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schid F, et al. A meta-Analysis of head-to-head comparisons of second-generation antipsychotics in the treatment ofschizophrenia. Am J Psychiatry in advance published november 17, 2008. doi: 10.1176/appi.ajp.2008.08030368

12. Leucht S, Corves C, Arbter D, Engel RR, Li CH, Davis JM. Second-generation vs first-generation antipsychotic drugs for schizophrenia: a meta-analysisi. The Lancet, early online oublication, 5 Dec 2008. doi: 10.1016/S0140-6736(08)61764-X.

13. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone and haloperidol in the treatment of patients with chronicschizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62.

14. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs inpatients with chronic schizophrenia. N Eng J Med 2005; 353:1209-23.

15. Stroup S, McEvoy J, Swartz M, Byerly MJ, Glick ID, CaniveJM, et al. The National Institute of Mental Health Clinical Antipsychotics Trails Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development. Schizophr Bull 2003;29 (1): 15-31.

16. Sacristán JA, Soto J, Galende I, Hylan TR. A review of methodologies for assessing drug effectiveness and a new proposal: randomized database studies. Clin Ther 1997; 19: 1510-7.

17. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215-8.

18. Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, et al. Effectiveness of AntipsychoticTreatments for Schizophrenia: Interim 6-Month Analysis From a Prospective Observational Study (IC-SOHO) Comparing Olanzapine, Quetiapine, Risperidone, and Haloperidol. J Clin Psychiatry 2004; 65: 312-21.

19. Haro JM, Salvador-Carulla LS. The SOHO (Schizophrenia Outpatient Health Outcome) Study: implications for the treatment of schizophrenia. CNS Drugs 2006;20(4):293-301.

20. Brunner E, Gargoloff P, Caro O, González C, Landa E, González CH, et al. The Intercontinental schizophrenia outpatient health outcomes study (IC-SOHO): initial 6 month findings of the sample in Latin America. Actas Esp Psiquiatr 2006; 34(1): 16-27.

21. Rovner J, Assunção S, Gargoloff P, Silva-Ibarra H, Aguilar-Gasca J, et al. Estado funcional y calidad de vida en pacientes latinoamericanos con esquizofrenia tratados con antipsicóticos atípico o típico: resultados de 12 meses del estudio intercontinental schizophrenia outpatients health outcomes (IC-SOHO) VERTEX, Rev Arg Psiquiat 2005; 16: 332-41.

22. Adrianzén C, Dossenbach M, Velásquez JD Holguín J, Leadbetter M. Effectiveness and Tolerability of Olanzapine vs risperidone vs typical antipsychotic medications: 3-Year results of the Schizophrenia Outpatient Health Outcomes Study (SOHO) in the Andean Region. Arc Neurocien 2007;12:86-94.

23. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007; 17: 235-44.

24. Ascher-Svanum H, Faries DE, Zhu F, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006; 67:453-460.

25. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;21;6:8.

26. Kinon BJ, Liu-Seifert H, Adams DH, Citrome L. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J Clin Psychopharmacol 2006; 26:632-7.

27. Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar- Perkovic D, et al. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a Pan-Continental Observational Study. J Clin Psychiatry September 9, 2008: e1-e15 (pii: ej08m04263).

28. Perez-Iglesias R, Crespo-Facorro B, Amado JA, García Unzueta MT, Ramírez-Bonilla ML, Gonzalez-Blanch C, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophrenia Research 2008; 99: 13-22

29. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-Term olanzapine treatment: weight change and weight related health factors in schizophrenia. J Clin Psychiatry 2001; 62:92-100.